Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Continuous support and monitoring by healthcare professionals ensure the safe and effective use of tirzepatide, helping patients achieve their weight loss goals and enhance their overall quality of life
Orforglipron Maintains Weight Loss in Patients Switching from Semaglutide or Tirzepatide Orforglipron has met the primary and all key secondary endpoints in the phase 3 ATTAIN-MAINTAIN trial by providing superior weight maintenance compared to placebo in patients enrolled from the phase 3 SURMOUNT-5 trial, as announced by parent company Eli Lilly and Company on December 18, 2025
Feeling cold is often a normal metabolic reaction to eating fewer calories
Joint stress decreases, sleep apnea severity often improves, and inflammation markers typically fall as fat mass decreases
